

# Australian Technical Advisory Group on Immunisation (ATAGI) recommended COVID-19 vaccines and doses

The table below summarises the ATAGI recommendations relating to COVID-19 vaccines for the **general population**. Please read corresponding footnotes for important guidance.

Information for severely immunocompromised individuals, and special populations is located on the following pages.

GENERAL POPULATION					
GROUP	VACCINE	PRIMARY COURSE	VACCINE	FIRST BOOSTER	SECOND BOOSTER
5 years	Pfizer (COMIRNATY) (Orange) <sup>1</sup> Moderna (SPIKEVAX) (Blue/Purple) <sup>2</sup>	FIRST DOSE → SECOND DOSE		Not recommended. <sup>6</sup>	
6 – 11 years	Pfizer (COMIRNATY) (Orange) <sup>1</sup>	FIRST DOSE → SECOND DOSE		Not recommended. <sup>6</sup>	
12 – 15 years	Pfizer (COMIRNATY) (Purple) <sup>3</sup> Novavax (NUVAXOVID) <sup>4</sup>	FIRST DOSE → SECOND DOSE		Not recommended. <sup>7</sup>	
16 – 17 years	Pfizer (COMIRNATY) (Purple) <sup>3</sup> Novavax (NUVAXOVID) <sup>4</sup>	FIRST DOSE → SECOND DOSE	Pfizer (COMIRNATY) (Purple) <sup>3,8</sup> [Novavax (NUVAXOVID)] <sup>4,9</sup>	FIRST BOOSTER 3 months after Primary Course.	Not recommended.
18 – 29 years	Pfizer (COMIRNATY) (Purple) <sup>3</sup> Novavax (NUVAXOVID) <sup>4</sup> AstraZeneca (VAXZEVRIA) <sup>5</sup>	FIRST DOSE → SECOND DOSE	Pfizer (COMIRNATY) (Purple) <sup>3,10</sup> Moderna (SPIKEVAX Bivalent) <sup>10,11</sup> Pfizer (COMIRNATY Bivalent) <sup>10,12</sup> Novavax (NUVAXOVID) <sup>4,10</sup> AstraZeneca (VAXZEVRIA) <sup>5,10</sup>	FIRST BOOSTER 3 months after Primary Course.	Not recommended. <sup>13</sup>
30 – 49 years	Pfizer (COMIRNATY) (Purple) <sup>3</sup> Novavax (NUVAXOVID) <sup>4</sup> AstraZeneca (VAXZEVRIA) <sup>5</sup>	FIRST DOSE → SECOND DOSE	Pfizer (COMIRNATY) (Purple) <sup>3,10</sup> Moderna (SPIKEVAX Bivalent) <sup>10,11</sup> Pfizer (COMIRNATY Bivalent) <sup>10,12</sup> Novavax (NUVAXOVID) <sup>4,10</sup> AstraZeneca (VAXZEVRIA) <sup>5,10</sup>	FIRST BOOSTER 3 months after Primary Course.	CONSIDER SECOND BOOSTER From 3 months after Booster. <sup>14</sup>
50 years+	Pfizer (COMIRNATY) (Purple) <sup>3</sup> Novavax (NUVAXOVID) <sup>4</sup> AstraZeneca (VAXZEVRIA) <sup>5</sup>	FIRST DOSE → SECOND DOSE	Pfizer (COMIRNATY) (Purple) <sup>3,10</sup> Moderna (SPIKEVAX Bivalent) <sup>10,11</sup> Pfizer (COMIRNATY Bivalent) <sup>10,12</sup> Novavax (NUVAXOVID) <sup>4,10</sup> AstraZeneca (VAXZEVRIA) <sup>5,10</sup>	FIRST BOOSTER 3 months after Primary Course.	SECOND BOOSTER From 3 months after Booster.

## Notes:

- Pfizer (COMIRNATY) 5-11 years (orange cap) vaccine is approved for individuals aged 5 to 11 years. Each multidose vial requires dilution with 1.3mL of saline. Each dose is 0.2mL (10µg).
- Moderna (SPIKEVAX) 6 months to 5 years (blue/purple) vaccine is approved for eligible individuals aged 6 months to 5 years. The multidose vial does not require dilution. Each dose is 0.25mL (25µg).
- Pfizer (COMIRNATY) 12 years+ (purple cap) vaccine is approved for individuals aged 12 years and older. Each multidose vial requires dilution with 1.8mL of saline. Each dose is 0.3mL (30µg).
- Novavax (NUVAXOVID) vaccine is approved for individuals aged 12 years and older. The multidose vial does not require dilution. Each dose is 0.5mL (5µg).
- AstraZeneca (VAXZEVRIA) vaccine is approved for individuals aged 18 years and older. The multidose vial does not require dilution. Each dose is 0.5mL.
- ATAGI does not recommend that a booster dose of COVID-19 vaccine be given to all children aged 5 to 11 years. There is insufficient evidence of severe disease in otherwise healthy children in this age group who have already received two primary doses of a COVID-19 vaccine.
- ATAGI does not recommend that a booster dose of COVID-19 vaccine be given to all adolescents aged 12-15 years. There is insufficient evidence of severe disease in otherwise healthy adolescents in this age group who have already received two primary doses of a COVID-19 vaccine.
- For people aged 12 to 17 years, Pfizer (COMIRNATY) 12 years+ (purple cap) vaccine is the only vaccine registered for use as a booster.
- Novavax (NUVAXOVID) vaccine is not registered by the TGA for use as a booster dose in adolescents aged 12 to 17 years, however ATAGI have advised that Novavax (NUVAXOVID) vaccine can be used as a booster in this age group if no other COVID-19 vaccine brand is suitable for that person.
- For people aged 18 years and older, Pfizer (COMIRNATY) 12 years+ (purple cap), Moderna (SPIKEVAX Bivalent) 18 years+ (blue/green) or Pfizer (COMIRNATY Bivalent) 18 years+ (grey cap) vaccines are preferred for a booster dose, regardless of which vaccine was used for the primary course. Although not preferred, AstraZeneca (VAXZEVRIA) vaccine or Novavax (NUVAXOVID) vaccine can be used as a booster dose in people aged 18 years and older for people who have a contraindication to mRNA vaccines (including those who have had a serious adverse event following mRNA vaccines, such as a history of anaphylaxis or myocarditis attributed to a mRNA vaccine) or for people who do not prefer a mRNA vaccine.
- Moderna (SPIKEVAX Bivalent) 18 years+ (blue/green) vaccine is approved as a booster dose for individuals aged 18 years and older. The multidose vial does not require dilution. Each dose is 0.5mL (50µg).
- Pfizer (COMIRNATY Bivalent) 18 years+ (grey cap) vaccine is approved as a booster dose for individuals aged 18 years and older. The multidose vial does not require dilution. Each dose is 0.3mL (30µg).
- At this moment, ATAGI does not support making the fourth dose available to healthy adults aged less than 30 years as it is unclear whether the benefits outweigh the risks in this population.
- People aged 30 to 49 years can receive a second booster dose of a COVID-19 vaccine, but the benefit for people in this age group is less certain. ATAGI encourages people in this age group to have a discussion with their regular medical provider to review their individual health needs and the benefits and risks of a second booster dose.

# Australian Technical Advisory Group on Immunisation (ATAGI) recommended COVID-19 vaccines and doses

The table below summarises the ATAGI recommendations relating to COVID-19 vaccines for individuals with **severe immunocompromise**. Please read corresponding footnotes for important guidance.

Information for the general population, and special populations, is located on separate pages.

SEVERELY IMMUNOCOMPROMISED POPULATIONS							
GROUP	VACCINE	PRIMARY COURSE			VACCINE	FIRST BOOSTER	SECOND BOOSTER
6 months – 4 years with severe immunocompromise. <sup>1,2</sup>	Moderna (SPIKEVAX) (Blue/Purple) <sup>4</sup> Pfizer (COMIRNATY) (Maroon) <sup>5</sup>	FIRST DOSE	→	SECOND DOSE	→	THIRD DOSE	Not approved or recommended.
							2 months after second dose. <sup>10</sup>
5 years with severe immunocompromise. <sup>1,3</sup>	Moderna (SPIKEVAX) (Blue/Purple) <sup>4</sup> Pfizer (COMIRNATY) (Orange) <sup>6</sup>	FIRST DOSE	→	SECOND DOSE	→	THIRD DOSE	Pfizer (COMIRNATY) (Orange) <sup>6</sup> FIRST BOOSTER 3 months after Primary Course. Not recommended.
							2 months after second dose. <sup>11</sup>
6 – 11 years with severe immunocompromise. <sup>1,3</sup>	Pfizer (COMIRNATY) (Orange) <sup>6</sup>	FIRST DOSE	→	SECOND DOSE	→	THIRD DOSE	Pfizer (COMIRNATY) (Orange) <sup>6</sup> FIRST BOOSTER 3 months after Primary Course. Not recommended.
							2 months after second dose. <sup>11</sup>
12 – 15 years with severe immunocompromise. <sup>1</sup>	Pfizer (COMIRNATY) (Purple) <sup>7</sup> Novavax (NUVAXOVID) <sup>8</sup>	FIRST DOSE	→	SECOND DOSE	→	THIRD DOSE	Pfizer (COMIRNATY) (Purple) <sup>7,12</sup> [Novavax (NUVAXOVID)] <sup>8,13</sup> FIRST BOOSTER 3 months after Primary Course. Not recommended.
							2 months after second dose. <sup>11</sup>
16 – 17 years with severe immunocompromise. <sup>1</sup>	Pfizer (COMIRNATY) (Purple) <sup>7</sup> Novavax (NUVAXOVID) <sup>8</sup>	FIRST DOSE	→	SECOND DOSE	→	THIRD DOSE	Pfizer (COMIRNATY) (Purple) <sup>7,12</sup> [Novavax (NUVAXOVID)] <sup>8,13</sup> FIRST BOOSTER 3 months after Primary Course. SECOND BOOSTER From 3 months after Booster.
							2 months after second dose. <sup>11</sup>
18 years+ with severe immunocompromise. <sup>1</sup>	Pfizer (COMIRNATY) (Purple) <sup>7</sup> Novavax (NUVAXOVID) <sup>8</sup> AstraZeneca (VAXZEVRIA) <sup>9</sup>	FIRST DOSE	→	SECOND DOSE	→	THIRD DOSE	Pfizer (COMIRNATY) (Purple) <sup>7,14</sup> Moderna (SPIKEVAX Bivalent) <sup>14,15</sup> Pfizer (COMIRNATY Bivalent) <sup>14,16</sup> Novavax (NUVAXOVID) <sup>8,14</sup> AstraZeneca (VAXZEVRIA) <sup>9,14</sup> FIRST BOOSTER 3 months after Primary Course. SECOND BOOSTER From 3 months after Booster.
							2 months after second dose. <sup>11</sup>

## Notes:

- Refer to ATAGI recommendations on the use of a third primary dose of COVID-19 vaccine in individuals who are severely immunocompromised: <https://www.health.gov.au/resources/publications/atagi-recommendations-on-the-use-of-a-third-primary-dose-of-covid-19-vaccine-in-individuals-who-are-severely-immunocompromised>
- Refer to ATAGI recommendations on COVID-19 vaccine use in children aged 6 months to <5 years: <https://www.health.gov.au/news/atagi-recommendations-on-covid-19-vaccine-use-in-children-aged-6-months-to-5-years>
- Refer to ATAGI recommendations for a booster dose of the Pfizer (COMIRNATY) 5-11 years (orange cap) vaccine in children aged 5 to 11 years: <https://www.health.gov.au/news/atagi-recommendations-for-a-booster-dose-of-the-paediatric-pfizer-covid-19-vaccine-in-children-aged-5-to-11-years>
- Moderna (SPIKEVAX) 6 months to 5 years (blue/purple) vaccine is approved for eligible individuals aged 6 months to 5 years. The multidose vial does not require dilution. Each dose is 0.25mL (25µg).
- Pfizer (COMIRNATY) 6 months to 4 years (maroon cap) vaccine is approved for eligible individuals aged 6 months to 4 years. Each multidose vial requires dilution with 2.2mL of saline. Each dose is 0.2mL (3µg). The recommended primary course dosing schedule is 3 doses, 8 weeks apart. Severely immunocompromised children who receive the 3-dose primary schedule of the Pfizer (COMIRNATY) 6 months to 4 years (maroon cap) vaccine do not require a fourth primary dose.
- Pfizer (COMIRNATY) 5-11 years (orange cap) vaccine is approved for individuals aged 5 to 11 years. Each multidose vial requires dilution with 1.3mL of saline. Each dose is 0.2mL (10µg).
- Pfizer (COMIRNATY) 12 years+ (purple cap) vaccine is approved for individuals aged 12 years and older. Each multidose vial requires dilution with 1.8mL of saline. Each dose is 0.3mL (30µg).
- Novavax (NUVAXOVID) vaccine is approved for individuals aged 12 years and older. The multidose vial does not require dilution. Each dose is 0.5mL (5µg). There is very limited evidence of the efficacy of Novavax in immunocompromised people.
- AstraZeneca (VAXZEVRIA) vaccine is approved for individuals aged 18 years and older. The multidose vial does not require dilution. Each dose is 0.5mL. AstraZeneca (VAXZEVRIA) vaccine is not preferred but can be used for the third primary dose in adults if there are contraindications to mRNA and Novavax (NUVAXOVID) vaccine.
- For Pfizer 6 months to 4 years (maroon cap) vaccine, ATAGI recommends a dosing schedule of 3 doses, 8 weeks apart. The dose can be shortened to a minimum of 3 weeks between the first and second dose, and a minimum of 8 weeks between the second and third dose. For Moderna (SPIKEVAX) 6 months to 5 years (blue/purple) vaccine, ATAGI recommends the third primary dose is given 8 weeks after the second primary dose, however, a minimum interval of 4 weeks may be considered in exceptional circumstances.
- The third primary dose should be given from 2 months after the second primary dose; however, ATAGI considers a minimum interval of 4 weeks to be acceptable for exceptional circumstances (e.g. anticipated intensification of immunosuppression).
- For people aged 12 to 17 years, Pfizer (COMIRNATY) 12 years+ (purple cap) vaccine is the only vaccine registered for use as a booster.
- Novavax (NUVAXOVID) vaccine is not registered by the TGA for use as a booster dose in adolescents aged 12 to 17 years, however ATAGI have advised that Novavax (NUVAXOVID) vaccine can be used as a booster in this age group if Pfizer (COMIRNATY) 12 years+ (purple cap) vaccine is not suitable for that person.
- For people aged 18 years and older, Pfizer (COMIRNATY) 12 years+ (purple cap), Moderna (SPIKEVAX Bivalent) 18 years+ (blue/green) or Pfizer (COMIRNATY Bivalent) (grey cap) vaccines are the preferred vaccines for a booster dose, regardless of which vaccine was used for the primary course. Although not preferred, AstraZeneca (VAXZEVRIA) vaccine or Novavax (NUVAXOVID) vaccine can be used as a booster dose in people aged 18 years and older for people who have a contraindication to mRNA vaccines (including those who have had a serious adverse event following mRNA vaccines, such as a history of anaphylaxis or myocarditis attributed to an mRNA vaccine) or for people who do not prefer an mRNA vaccine.
- Moderna (SPIKEVAX Bivalent) 18 years+ (blue/green) vaccine is approved as a booster dose for individuals aged 18 years and older. The multidose vial does not require dilution. Each dose is 0.5mL (50µg).
- Pfizer (COMIRNATY Bivalent) 18 years+ (grey cap) vaccine is approved as a booster dose for individuals aged 18 years and older. The multidose vial does not require dilution. Each dose is 0.3mL (30µg).

Detailed information on ATAGI clinical recommendations for COVID-19 vaccines is available at: [www.health.gov.au/initiatives-and-programs/covid-19-vaccines/advice-for-providers/clinical-guidance/clinical-recommendations](https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/advice-for-providers/clinical-guidance/clinical-recommendations). Information current as of 18 January 2023.

# Australian Technical Advisory Group on Immunisation (ATAGI) recommended COVID-19 vaccines and doses

The table below summarises the ATAGI recommendations relating to COVID-19 vaccines for **special populations**. Please read corresponding footnotes for important guidance.

Information for the general population, and for severely immunocompromised individuals, is located on separate pages.

SPECIAL POPULATIONS							
GROUP	VACCINE	PRIMARY COURSE			VACCINE	FIRST BOOSTER	SECOND BOOSTER
6 months – 4 years with disability, or those who have complex and/or multiple health conditions which increase the risk of severe COVID-19. <sup>1</sup>	Moderna (SPIKEVAX) (Blue/Purple) <sup>6</sup>	FIRST DOSE → SECOND DOSE			Not approved or recommended.		
	Pfizer (COMIRNATY) (Maroon) <sup>7</sup>	FIRST DOSE → SECOND DOSE → THIRD DOSE					
5 years who have a disability with significant or complex health needs, or who have complex and/or multiple health conditions that increase the risk of severe COVID-19. <sup>2</sup>	Moderna (SPIKEVAX) (Blue/Purple) <sup>6</sup> Pfizer (COMIRNATY) (Orange) <sup>8</sup>	FIRST DOSE → SECOND DOSE			Pfizer (COMIRNATY) (Orange) <sup>8</sup>	FIRST BOOSTER 3 months after Primary Course	Not recommended.
6 – 11 years who have a disability with significant or complex health needs, or who have complex and/or multiple health conditions that increase the risk of severe COVID-19. <sup>2</sup>	Pfizer (COMIRNATY) (Orange) <sup>8</sup>	FIRST DOSE → SECOND DOSE			Pfizer (COMIRNATY) (Orange) <sup>8</sup>	FIRST BOOSTER 3 months after Primary Course	Not recommended.
12 – 15 years who have a disability with significant or complex health needs, or who have complex and/or multiple health conditions that increase the risk of severe COVID-19. <sup>3</sup>	Pfizer (COMIRNATY) (Purple) <sup>9</sup> Novavax (NUVAXOVID) <sup>10</sup>	FIRST DOSE → SECOND DOSE			Pfizer (COMIRNATY) (Purple) <sup>9,13</sup> [Novavax (NUVAXOVID)] <sup>10,14</sup>	FIRST BOOSTER 3 months after Primary Course	Not recommended.
Pregnant, breastfeeding or planning pregnancy. <sup>4</sup>	Pfizer (COMIRNATY) (Purple) <sup>9,12</sup> Novavax (NUVAXOVID) <sup>10,12</sup> AstraZeneca (VAXZEVRIA) <sup>11,12</sup>	FIRST DOSE → SECOND DOSE			Pfizer (COMIRNATY) (Purple) <sup>9,15</sup> Moderna (SPIKEVAX Bivalent) <sup>15,16</sup> Pfizer (COMIRNATY Bivalent) <sup>15,17</sup> Novavax (NUVAXOVID) <sup>10,15</sup> AstraZeneca (VAXZEVRIA) <sup>11,15</sup>	FIRST BOOSTER 3 months after Primary Course.	Not recommended. <sup>18</sup>
16 years+ who are residents of aged care or disability care facilities, who have complex, chronic or severe conditions that increase their risk of severe COVID-19 illness, or those with disability, significant or complex health needs, or multiple comorbidities which increase the risk of a poor outcome from COVID-19. <sup>5</sup>	Pfizer (COMIRNATY) (Purple) <sup>9</sup> Novavax (NUVAXOVID) <sup>10</sup> AstraZeneca (VAXZEVRIA) <sup>11</sup>	FIRST DOSE → SECOND DOSE			Pfizer (COMIRNATY) (Purple) <sup>9,15</sup> Moderna (SPIKEVAX Bivalent) <sup>15,16</sup> Pfizer (COMIRNATY Bivalent) <sup>15,17</sup> Novavax (NUVAXOVID) <sup>10,15</sup> AstraZeneca (VAXZEVRIA) <sup>11,15</sup>	FIRST BOOSTER 3 months after Primary Course.	SECOND BOOSTER From 3 months after Booster.

## Notes:

- Refer to ATAGI recommendations on COVID-19 vaccine use in children aged 6 months to <5 years: <https://www.health.gov.au/news/atagi-recommendations-on-use-of-the-pfizer-covid-19-vaccine-for-children-aged-6-months-to-4-years?language=en>
- Refer to ATAGI recommendations for a booster dose of the Pfizer (COMIRNATY) 5-11 years (orange cap) vaccine in children aged 5 to 11 years: <https://www.health.gov.au/news/atagi-recommendations-for-a-booster-dose-of-the-paediatric-pfizer-covid-19-vaccine-in-children-aged-5-to-11-years>
- Refer to ATAGI recommendations on first booster dose in adolescents aged 12 to 15 years: <https://www.health.gov.au/news/atagi-recommendations-on-first-booster-dose-in-adolescents-aged-12-15-years>
- Refer to Pregnancy, breastfeeding and COVID-19 vaccines: <https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/who-can-get-vaccinated/pregnant-women>
- Refer to ATAGI updated recommendations for a fourth dose of COVID-19 vaccine: <https://www.health.gov.au/news/atagi-updated-recommendations-for-a-winter-dose-of-covid-19-vaccine>
- Moderna (SPIKEVAX) 6 months to 5 years (blue/purple) vaccine is approved for eligible individuals aged 6 months to 5 years. The multidose vial does not require dilution. Each dose is 0.25mL (25µg).
- Pfizer (COMIRNATY) 6 months to 4 years (maroon cap) vaccine is approved for eligible individuals aged 6 months to 4 years. Each multidose vial requires dilution with 2.2mL of saline. Each dose is 0.2mL (3µg). The recommended primary course dosing schedule is 3 doses, 8 weeks apart.
- Pfizer (COMIRNATY) 5-11 years (orange cap) vaccine is approved for individuals aged 5 to 11 years. Each multidose vial requires dilution with 1.3mL of saline. Each dose is 0.2mL (10µg).
- Pfizer (COMIRNATY) 12 years+ (purple cap) vaccine is approved for individuals aged 12 years and older. Each multidose vial requires dilution with 1.8mL of saline. Each dose is 0.3mL (30µg).
- Novavax (NUVAXOVID) vaccine is approved for individuals aged 12 years and older. The multidose vial does not require dilution. Each dose is 0.5mL (5µg).
- AstraZeneca (VAXZEVRIA) vaccine is approved for individuals aged 18 years and older. The multidose vial does not require dilution. Each dose is 0.5mL.
- Pfizer (COMIRNATY) 12 years+ (purple cap) is recommended for pregnant and breastfeeding women and those planning a pregnancy. If they cannot have this vaccine, they can have the Novavax (NUVAXOVID) or AstraZeneca (VAXZEVRIA) vaccine.
- For people aged 12 to 17 years, Pfizer (COMIRNATY) 12 years+ (purple cap) vaccine is the only vaccine registered for use as a booster.
- Novavax (NUVAXOVID) vaccine is not registered by the TGA for use as a booster dose in adolescents aged 12 to 17 years, however can be used as a booster in this age group if Pfizer (COMIRNATY) 12 years+ (purple cap) vaccine is not suitable for that person.
- For people aged 18 years and older, Pfizer (COMIRNATY) 12 years+ (purple cap), Moderna (SPIKEVAX Bivalent) 18 years+ (blue/green) or Pfizer (COMIRNATY Bivalent) (grey cap) vaccines are the preferred vaccines for a booster dose, regardless of which vaccine was used for the primary course. Although not preferred, AstraZeneca (VAXZEVRIA) vaccine or Novavax (NUVAXOVID) vaccine can be used as a booster dose in people aged 18 years and older for people who have a contraindication to mRNA vaccines (including those who have had a serious adverse event following mRNA vaccines, such as a history of anaphylaxis or myocarditis attributed to an mRNA vaccine) or for people who do not prefer an mRNA vaccine.
- Moderna (SPIKEVAX Bivalent) 18 years+ (blue/green) vaccine is approved as a booster dose for individuals aged 18 years and older. The multidose vial does not require dilution. Each dose is 0.5mL (50µg).
- Pfizer (COMIRNATY Bivalent) 18 years+ (grey cap) vaccine is approved as a booster dose for individuals aged 18 years and older. The multidose vial does not require dilution. Each dose is 0.3mL (30µg).
- Pregnant women aged 30 years and older may receive a second booster dose (a fourth dose) of COVID-19 vaccine. ATAGI does not specifically recommend a second booster dose for healthy adults aged 30 to 49 years but encourages people in this age group to have a discussion with their regular medical provider to review their individual health needs and consider the benefits and risks of a second booster dose.

Detailed information on ATAGI clinical recommendations for COVID-19 vaccines is available at: [www.health.gov.au/initiatives-and-programs/covid-19-vaccines/advice-for-providers/clinical-guidance/clinical-recommendations](http://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/advice-for-providers/clinical-guidance/clinical-recommendations). Information current as of 18 January 2023.